Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDR | P35968 | 14/20 | 0.67 |
| ▸ | SRC | P12931 | 2/20 | 0.67 |
| ▸ | EPHA2 | P29317 | 15/20 | 0.56 |
| ▸ | EPHB4 | P54760 | 10/20 | 0.54 |
| ▸ | ERBB2 | P04626 | 8/20 | 0.53 |
| ▸ | FLT1 | P17948 | 4/20 | 0.52 |
| ▸ | RET | P07949 | 1/20 | 0.52 |
| ▸ | KIF5B | P33176 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6445629 | 1.00 | KDR (0.67) | KDRSRCEPHA2EPHB4ERBB2 | |
| SCHEMBL6445304 | 0.87 | KDR (0.66) | KDRSRCEPHA2EPHB4ERBB2 | |
| SCHEMBL6448818 | 0.84 | KDR (0.67) | KDRSRCEPHA2EPHB4ERBB2 | |
| SCHEMBL6445316 | 0.82 | KDR (0.81) | KDRSRCEPHA2EPHB4FLT1 | |
| SCHEMBL6448196 | 0.82 | KDR (0.74) | KDRSRCEPHA2EPHB4ERBB2 | |
| SCHEMBL6445791 | 0.82 | KDR (0.66) | KDRSRCEPHA2EPHB4ERBB2 | |
| SCHEMBL6445013 | 0.82 | KDR (0.80) | KDRSRCEPHA2EPHB4FLT1 | |
| SCHEMBL3673614 | 0.82 | KDR (0.88) | KDRSRCEPHA2EPHB4FLT1 | |
| SCHEMBL6446670 | 0.82 | KDR (0.63) | KDRSRCFLT1RETKIF5B | |
| SCHEMBL3680310 | 0.81 | KDR (0.87) | KDRSRCEPHB4ERBB2FLT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6849625-B2 | Quinazoline derivatives with anti-tumour activity | ASTRAZENECA AB (SE) | 2005-02-01 | — | — | US | disclosed |
| US-20040048881-A1 | Quinazoline derivatives with anti-tumour activity | ASTRAZENECA AB (SE) | 2004-03-11 | — | — | US | disclosed |
| EP-1326859-A1 | QUINAZOLINE DERIVATIVES WITH ANTI-TUMOUR ACTIVITY | AstraZeneca AB (SE) | 2003-07-16 | — | — | EP | disclosed |
| WO-2002030924-A9 | QUINAZOLINE DERIVATIVES WITH ANTI-TUMOUR ACTIVITY | ASTRAZENECA AB (SE) | 2003-05-22 | — | — | WO | disclosed |
| WO-2002030924-A1 | QUINAZOLINE DERIVATIVES WITH ANTI-TUMOUR ACTIVITY | ASTRAZENECA AB (SE) | 2002-04-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040048881-A1 | Quinazoline derivatives with anti-tumour activity | TOP1, NQO2, ABCC1 | KDR 2192/4885SRC 2823/4885EPHA2 3999/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.